Teva Pharmaceutical profit, revenue rise in fourth quarter

Core Viewpoint - Teva Pharmaceutical Industries reported a higher-than-expected increase in fourth-quarter profit, driven by sales of branded drugs and a milestone payment for a late-stage study on ulcerative colitis and Crohn's disease [1] Financial Performance - The company experienced a significant rise in fourth-quarter profit, surpassing market expectations [1] Product Development - The profit increase was supported by sales of its branded drugs and a milestone payment related to the initiation of a late-stage study for treating ulcerative colitis and Crohn's disease [1]